{"generic":"Griseofulvin, Microcrystalline","drugs":["Fulvicin-U\/F","Grifulvin V","Griseofulvin, Microcrystalline"],"mono":{"0":{"id":"264169-s-0","title":"Generic Names","mono":"Griseofulvin, Microcrystalline"},"1":{"id":"264169-s-1","title":"Dosing and Indications","sub":{"0":{"id":"264169-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Onychomycosis due to dermatophyte:<\/b> 1 g ORALLY once a day for at least 4 months (fingernails) or at least 6 months (toenails)<\/li><li><b>Tinea barbae:<\/b> 500 mg ORALLY once a day until infection has cleared<\/li><li><b>Tinea capitis:<\/b> 500 mg ORALLY once a day for 4 to 6 weeks<\/li><li><b>Tinea corporis:<\/b> 500 mg ORALLY once a day for 2 to 4 weeks<\/li><li><b>Tinea cruris:<\/b> 500 mg ORALLY once a day until infection has cleared<\/li><li><b>Tinea pedis:<\/b> 1 g ORALLY once a day for 4 to 8 weeks<\/li><\/ul>"},"1":{"id":"264169-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Onychomycosis due to dermatophyte:<\/b> (30 to 50 pounds) 125 to 250 mg ORALLY once daily for at least 4 months (fingernails) or at least 6 months (toenails)<\/li><li><b>Onychomycosis due to dermatophyte:<\/b> (greater than 50 pounds) 250 to 500 mg ORALLY once daily for at least 4 months (fingernails) or at least 6 months (toenails)<\/li><li><b>Tinea barbae:<\/b> (30 to 50 pounds) 125 to 250 mg ORALLY once daily until infection has cleared<\/li><li><b>Tinea barbae:<\/b> (greater than 50 pounds) 250 to 500 mg ORALLY once daily until infection has cleared<\/li><li><b>Tinea capitis:<\/b> (30 to 50 pounds) 125 to 250 mg ORALLY once daily for 4 to 6 weeks<\/li><li><b>Tinea capitis:<\/b> (greater than 50 pounds) 250 to 500 mg ORALLY once daily for 4 to 6 weeks<\/li><li><b>Tinea corporis:<\/b> (30 to 50 pounds) 125 to 250 mg ORALLY once daily for 2 to 4 weeks<\/li><li><b>Tinea corporis:<\/b> (greater than 50 pounds) 250 to 500 mg ORALLY once daily for 2 to 4 weeks<\/li><li><b>Tinea cruris:<\/b> (30 to 50 pounds) 125 to 250 mg ORALLY once daily until infection has cleared<\/li><li><b>Tinea cruris:<\/b> (greater than 50 pounds) 250 to 500 mg ORALLY once daily until infection has cleared<\/li><li><b>Tinea pedis:<\/b> (30 to 50 pounds) 125 to 250 mg ORALLY once daily for 4 to 8 weeks<\/li><li><b>Tinea pedis:<\/b> (greater than 50 pounds) 250 to 500 mg ORALLY once daily for 4 to 8 weeks<\/li><\/ul>"},"3":{"id":"264169-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Onychomycosis due to dermatophyte<\/li><li>Tinea barbae<\/li><li>Tinea capitis<\/li><li>Tinea corporis<\/li><li>Tinea cruris<\/li><li>Tinea pedis<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><br\/>Lichen planus, Cutaneous<br\/>"}}},"3":{"id":"264169-s-3","title":"Contraindications\/Warnings","sub":[{"id":"264169-s-3-9","title":"Contraindications","mono":"<ul><li>hypersensitivity to griseofulvin products<\/li><li>patients with porphyria and hepatocellular failure<\/li><li>pregnancy or intention to become pregnant within 1 month of stopping therapy<\/li><\/ul>"},{"id":"264169-s-3-10","title":"Precautions","mono":"<ul><li>additional contraceptive precautions should be taken during therapy and for 1 month following therapy<\/li><li>males should wait at least 6 months after therapy before fathering a child<\/li><li>history of penicillin allergy<\/li><li>photosensitivity; avoid excessive exposure to sunlight<\/li><\/ul>"},{"id":"264169-s-3-11","title":"Pregnancy Category","mono":"Griseofulvin: B3 (AUS)<br\/>"},{"id":"264169-s-3-12","title":"Breast Feeding","mono":"<ul><li>Griseofulvin: WHO: WHO documentation states insufficient data.<\/li><li>Griseofulvin: Micromedex: Infant risk cannot be ruled out.<\/li><\/ul>"}]},"4":{"id":"264169-s-4","title":"Drug Interactions","sub":{"2":{"id":"264169-s-4-15","title":"Moderate","mono":"<ul><li>Desogestrel (established)<\/li><li>Dienogest (established)<\/li><li>Drospirenone (established)<\/li><li>Estradiol Cypionate (established)<\/li><li>Estradiol Valerate (established)<\/li><li>Ethinyl Estradiol (established)<\/li><li>Ethynodiol Diacetate (established)<\/li><li>Etonogestrel (established)<\/li><li>Levonorgestrel (established)<\/li><li>Medroxyprogesterone Acetate (established)<\/li><li>Mestranol (established)<\/li><li>Norelgestromin (established)<\/li><li>Norethindrone (established)<\/li><li>Norgestimate (established)<\/li><li>Norgestrel (established)<\/li><li>Phenobarbital (probable)<\/li><li>Warfarin (probable)<\/li><\/ul>"}}},"5":{"id":"264169-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Photosensitivity, Rash, Urticaria<\/li><li><b>Gastrointestinal:<\/b>Diarrhea, Nausea, Vomiting<\/li><li><b>Neurologic:<\/b>Headache<\/li><\/ul><b>Serious<\/b><br\/><b>Neurologic:<\/b>Acroparesthesia (rare)<br\/>"},"6":{"id":"264169-s-6","title":"Drug Name Info","sub":{"0":{"id":"264169-s-6-17","title":"US Trade Names","mono":"<ul><li>Grifulvin V<\/li><li>Fulvicin-U\/F<\/li><\/ul>"},"2":{"id":"264169-s-6-19","title":"Class","mono":"Antifungal<br\/>"},"3":{"id":"264169-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"264169-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"264169-s-7","title":"Mechanism Of Action","mono":"Griseofulvin is a fungistatic antibiotic that systemically inhibits fungal growth by depositing the in the keratin and exfoliation of the infected tissue.<br\/>"},"8":{"id":"264169-s-8","title":"Pharmacokinetics","sub":[{"id":"264169-s-8-23","title":"Absorption","mono":"<ul><li>Oral: time to peak concentration, about 4 h<\/li><li>Effect of food: better blood levels with a high fat meal<\/li><\/ul>"}]},"9":{"id":"264169-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>may take after a meal with high fat content to achieve better blood levels<\/li><li>(suspension) shake well before measuring dose<\/li><\/ul>"},"10":{"id":"264169-s-10","title":"Monitoring","mono":"<ul><li>negative culture or improvement of clinical signs and symptoms of infection<\/li><li> hematopoietic, hepatic and renal function with prolonged therapy<\/li><\/ul>"},"11":{"id":"264169-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/><ul><li>Oral Capsule: 250 MG<\/li><li>Oral Suspension: 125 MG\/5 ML<\/li><li>Oral Tablet: 250 MG, 500 MG<\/li><\/ul><\/li><li><b>Grifulvin V<\/b><br\/><ul><li>Oral Suspension: 125 MG\/5 ML<\/li><li>Oral Tablet: 500 MG<\/li><\/ul><\/li><\/ul>"},"13":{"id":"264169-s-13","title":"Clinical Teaching","mono":"<ul><li>Drug may cause sun-sensitivity. Advise patient to use sunscreen and avoid tanning beds.<\/li><li>Adverse effects to a fetus may be caused by either male or female patients receiving treatment with this drug. Emphasize the use of reliable contraception to patient. This applies during treatment and up to 1 month post therapy for women and 6 months post therapy for men.<\/li><li>This drug may cause rash, urticaria, diarrhea, nausea, vomiting, or headache.<\/li><li>Patient should take drug after a meal with a high fat content.<\/li><\/ul>"}}}